BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28388991)

  • 1. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Immunologic Approaches to Melanoma Treatment.
    Escandell I; Martín JM; Jordá E
    Actas Dermosifiliogr; 2017 Oct; 108(8):708-720. PubMed ID: 28527857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of immunotherapy in the treatment of melanoma.
    Achkar T; Tarhini AA
    J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and PD-L1 antibodies for melanoma.
    Tsai KK; Zarzoso I; Daud AI
    Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma: smart therapeutic strategies in immuno-oncology.
    Eggermont AM; Robert C
    Nat Rev Clin Oncol; 2014 Apr; 11(4):181-2. PubMed ID: 24590131
    [No Abstract]   [Full Text] [Related]  

  • 8. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
    Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
    Front Immunol; 2019; 10():990. PubMed ID: 31134073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Biomarkers for Melanoma Immunotherapy.
    Twitty CG; Huppert LA; Daud AI
    Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Metastatic Melanoma in 2018.
    Kaufman HL; Margolin K; Sullivan R
    JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 19. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.